Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Open-label, Two-arm Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-volume Pre-exposure Prophylaxis (PrEP) Sites in the U.S. for HIV Uninfected MSM and Transgender Men ≥ 18

NCT05374525 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT05374525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05374525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Open-label, Two-arm Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-volume Pre-exposure Prophylaxis (PrEP) Sites in the U.S. for HIV Uninfected MSM and Transgender Men ≥ 18
Lead sponsor
ViiV Healthcare
Phase
Phase 4
Overall status
Completed
Start date
May 18, 2022
Completion date
August 8, 2024
Enrollment
287 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections